Viking Therapeutics Q3 EPS $(0.23) Misses $(0.22) Estimate
Portfolio Pulse from bharat@benzinga.com
Viking Therapeutics reported Q3 losses of $(0.23) per share, missing the analyst consensus estimate of $(0.22) by 4.55 percent. This represents a 9.52 percent decrease over losses from the same period last year.
October 25, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Viking Therapeutics' Q3 earnings per share missed estimates, with losses increasing year-on-year. This could negatively impact investor sentiment.
Earnings reports are a key indicator of a company's financial health. Missing estimates and reporting increased losses year-on-year is generally seen as negative by investors, which could lead to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100